ADT1318-Infliximab Biosimilar-Anti-TNF-alpha mAb-Research Grade

Catalog Number

ADT1318

Product Name

ADT1318-Infliximab Biosimilar-Anti-TNF-alpha mAb-Research Grade

Clonity

Monoclonal

Alternate Names

anti human TNFα antibody,  anti human TNF alpha antibody,  TNF alpha monoclonal antibody,  anti-mouse TNFα antibody,  anti-TNFα antibody,  anti TNFα antibody,  recombinant TNFα,  TNFα antibody,  anti-TNFα monoclonal antibody,  TNFα antibodies,  TNF alpha recombinant antibody,  TNF alpha blocking antibody

Alias

TA-650,  cA2

Host

CHO Cells

Species

Human

Target

TNF alpha

Gene ID

7124

Isotype

IgG1 Kappa

Size

1mg, 5mg

Research Area

Immunology

CAS Number

170277-31-3

Chemical Formula

C6428H9912N1694O1987S46

Product Description

Infliximab,  a chimeric monoclonal antibody,  sold under the brand name Remicade among others,  is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease,  ulcerative colitis,  rheumatoid arthritis,  ankylosing spondylitis,  psoriasis,  psoriatic arthritis,  and Behçet's disease.

Mechanism of Action

Infliximab is a IgG1κ monoclonal antibody that binds to soluble and transmembrane forms of TNF-α with high affinity to disrupt the pro-inflammatory cascade signalling. Binding of the antibody to TNF-α prevents TNF-α from interacting with its receptors. Infliximab does not neutralize TNF-β (lymphotoxin-α),  a related cytokine that utilizes the same receptors as TNF-α. Blocked actions of TNF-α further leads to downregulation of local and systemic pro-inflammatory cytokines (i.e. IL-1,  IL-6),  reduction of lymphocyte and leukocyte migration to sites of inflammation,  induction of apoptosis of TNF-producing cells (i.e. activated monocytes and T lymphocytes),  increased levels of nuclear factor-κB Inhibitionitor,  and reduction of reduction of endothelial adhesion molecules and acute phase proteins. Its Inhibitionitory actions on TNF-α was demonstrated in human fibroblasts,  endothelial cells,  neutrophils,  B and Tlymphocytes and epithelial cells. Infliximab also atteunates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes. According to a transgenic mice study that developed polyarthritis due to consitutive levels of human TNF-α,  infliximab decreased synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.

Metabolism

Infliximab has a long half-life,  typically ranging from 7 to 12 days.

Molecular Weight

144.19 KDa

Application

IF,  IP,  Neut,  Functional assay,  ELISA,  FC,  WB

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS,  PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reactivity

Human

Reference